靶向B细胞治疗免疫介导性肾脏疾病:KDIGO争议会议结论
KDIGO于2025年6月在巴拿马城召开争议会议,综述B细胞清除或调节疗法在多种免疫介导性肾小球疾病中的现有证据与研究缺口。会议指出不同疾病疗效差异显著:抗CD20在膜性肾病已成一线,在IgA肾病疗效有限,CAR T细胞在狼疮肾炎和ANCA相关肾炎中显示前景但需谨慎选择患者。
要点
- 膜性肾病中抗CD20抗体已成一线,多数患者18个月内达至少部分缓解。
- IgA肾病中利妥昔单抗疗效有限,BAFF/APRIL抑制剂和抗CD38抗体可降蛋白尿。
- CAR T细胞治疗狼疮肾炎和ANCA相关肾炎有前景,但需警惕细胞因子释放综合征。
核心结论
- B细胞靶向治疗在不同免疫介导性肾小球疾病中疗效和安全性差异显著,需疾病特异性应用。
研究设计与样本
- KDIGO于2025年6月在巴拿马城召开争议会议,综述现有证据并识别知识缺口和研究需求。
主要发现
- IgA肾病中抗CD20(利妥昔单抗)疗效有限,BAFF和APRIL抑制剂及抗CD38抗体可减少蛋白尿和eGFR下降。
- 膜性肾病中抗CD20抗体已成一线治疗,多数患者18个月内达至少部分缓解。
- 激素依赖性肾病综合征中利妥昔单抗可有效预防复发,尤其儿童,但获益短暂。
- 狼疮肾炎中奥妥珠单抗和CAR T细胞显示有前景结果,CAR T细胞可能实现长期无疾病活动且免治疗。
- ANCA相关肾小球肾炎中利妥昔单抗对诱导和维持治疗均有效,CAR T细胞试验正在进行。
关键数值与推荐
- 常规抗CD20治疗安全性良好,CAR T细胞治疗因细胞因子释放综合征等严重不良事件风险需仔细选择患者。
- 验证用于患者选择和监测的生物标志物是关键研究需求,同时需优化治疗方案和确定最佳疗程。
临床怎么用
- 膜性肾病可优先考虑抗CD20抗体一线治疗,IgA肾病需评估BAFF/APRIL或抗CD38等替代靶点。
- 激素依赖性肾病综合征儿童可用利妥昔单抗预防复发,但需关注获益短暂。
- CAR T细胞治疗应严格选择患者并监测细胞因子释放综合征等不良事件。
局限性
- 会议为争议会议综述,未提供系统检索策略或定量合并分析。
- 部分疗法证据来自早期研究,生物标志物验证和治疗疗程优化仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Treatments that deplete or modulate B cells are in use or being investigated for several immune-mediated glomerular diseases. Kidney Disease: Improving Global Outcomes (KDIGO) convened a Controversies Conference in Panama City, Panama, in June 2025 to review current evidence and identify key gaps in knowledge and research needs to effectively apply such therapies. Availability, effectiveness, and safety of B cell-targeted therapies vary substantially across glomerular diseases. In IgA nephropathy, anti-CD20 therapy (rituximab) has shown limited efficacy, although inhibitors of survival factors BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand) and anti-CD38 antibodies can lead to reduction in proteinuria and reduction in decline in estimated glomerular filtration rate. In contrast, for membranous nephropathy, anti-CD20 antibodies have become first-line therapy, achieving at least partial remission in most patients by 18 months. In steroid-dependent nephrotic syndrome, rituximab effectively prevents relapses, particularly in children, though benefits are transient. For lupus nephritis, newer approaches including obinutuzumab and chimeric antigen receptor (CAR) T cell therapy have shown promising results, with CAR T cells introducing the possibility of being free of disease activity and treatment for a prolonged time. In antineutrophil cytoplasmic antibody-associated glomerulonephritis, rituximab has proven effective for both induction and maintenance therapy, with ongoing trials investigating CAR T cell approaches. Safety considerations of B cell-targeting therapies vary by intensity of therapy, with conventional anti-CD20 therapy showing favorable safety profiles and CAR T cell therapy requiring careful patient selection because of the potential for cytokine release syndrome and other serious adverse events. Validating biomarkers for patient selection and monitoring is a critical research need, along with optimizing treatment protocols and determining optimal therapy duration.
引用
- Floege J, Ayoub I, Brix SR, et al. Targeting B cells in immune-mediated kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2026. PMID: 42034308. doi:10.1016/j.kint.2026.02.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。